ValeAnt.com
Title
Valeant Pharmaceuticals International | Home
Description
Valeant Pharmaceuticals ended 2005 with strong top and bottom line results marking yet another year of solid progress. For the 12th consecutive quarter we grew our specialty pharmaceutical business at better than industry average by focusing on business development expansion and growth in our promoted brands. Equally as impressive is the fact that Valeant reached all of its challenging operating targets, made excellent strides in driving operating efficiencies and strengthened its cash flow position. These achievements can primarily be attributed to Valeant’s relentless focus on execution.
Valeant began 2005 with a commitment to revenue expansion and continued control of expenses. One need not look past our substantial improvement in both top and bottom-line results to see that we were successful in doing what we set out to do. The company’s results are impressive considering the substantial investments that we made in our future through increased research and development, and promotional activities.
Acquisitions have been a core component of the company’s growth strategy. Strong product sales were driven by products we acquired from Xcel Pharmaceuticals, which we successfully expanded through line extensions and increased promotional activity. Our efforts led to a 32 percent increase in pro forma sales for these products over the level Xcel recorded last year. In addition, we closed out the year by adding to our impressive portfolio with the acquisition of Infergen, which is indicated for use in patients with hepatitis C who have failed previous treatment. The purchase of Infergen was a significant step forward in our plans to build Valeant’s infectious disease franchise.
Languages
English
Contact
Administrative:
- Domain Manager
-
- Aliso Viejo CA
- United States 92656
-
- +1.7145450100
Registrant:
- Valeant Pharmaceuticals International
-
- Aliso Viejo CA
- United States 92656
Logos
Additional Information
Related Domains
External Links
- Stock: VRX
- Alexa: ValeAnt.com
